Clinical Evaluation of the Antidepressant Effect of the Use of Probiotics in Bipolar Disorder

Last updated: December 1, 2023
Sponsor: University of Sao Paulo
Overall Status: Active - Recruiting

Phase

N/A

Condition

Bipolar Disorder

Mood Disorders

Treatment

Placebo Group

Probiotic Group

Clinical Study ID

NCT05762887
U1111-1280-7625
  • Ages 18-65
  • All Genders

Study Summary

Bipolar Disorder (BD) is highly incapacitating and associated with premature mortality. Depressive symptoms and episodes are the most frequent cause of disability in subjects with BD and over half of patients do not respond adequately to approved treatments for this condition, showing the need for new classes of treatments to complement current pharmacotherapy. Previous studies demonstrated that the intestinal flora have potential positive or negative effects on the Central Nervous System and suggest that adding specific strains of bacteria to people's diet may have antidepressant properties.The study proposes to evaluate the clinical benefit of adding probiotics to pharmacological treatments for bipolar depression. This will be a study with 84 subjects (42 receiving probiotics and 42 placebo). The research team in this department has focused especially on non-pharmacological treatments for bipolar disorder (psychotherapy, nutrition and exercise) and is multidisciplinary in scope with psychiatrists, psychologists, nurses, physiotherapists and nutritionists participating in research projects.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • BD type I or type II, according to the use of Mini Internacional NeuropsychiatricInterview (MINI)
  • Score on the Young Mania Rating Scale (YMRS) < 8
  • Score on the Montgomery-Asberg Depression Rating Scale (MADRS) > 8
  • Be receiving major guideline-approved treatments for bipolar depression for at least 4weeks

Exclusion

Exclusion Criteria:

  • Pregnant or lactating women
  • Substance or alcohol dependence
  • Patients on prolonged antibiotic therapy, immunosuppressive therapies
  • A recent introduction of antidepressants in the last 15 days
  • Use of another probiotic, either in the form of food, sachets, capsules and others

Study Design

Total Participants: 84
Treatment Group(s): 2
Primary Treatment: Placebo Group
Phase:
Study Start date:
January 09, 2023
Estimated Completion Date:
December 30, 2024

Study Description

It will test, in a proof-of-concept study, the antidepressant efficacy of adjunctive administration of probiotics in bipolar depression and evaluate potential inflammatory and metabolic markers associated with response to treatment. With this objective, 84 individuals with bipolar disorder type I or type II presenting subsyndromal depressive symptoms or a major depressive episode will be recruited. The study design lasts 12 weeks and is expected to last two years.

Connect with a study center

  • University of Sao Paulo

    São Paulo, Sao Paulo 05403010
    Brazil

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.